2023.7.13
042
164
字数：2800+
4、PreA至B轮前
Cytovation是挪威一家免疫肿瘤药物研发商，专注于开发靶向肿瘤膜免疫疗法，主要产品CyPep-1是一种针对肿瘤细胞细胞膜的肿瘤溶解剂。近日800万美元A+轮融资，Canica、Sandwater投资。
鉴于CyPep-1的巨大潜力，Cytovation AS最近宣布扩大其高级管理团队，聘请制药博士Iman Barilero担任首席研发官，MBA Helen Blanco担任运营副总裁。
Led by Lars Prestegarden, MD, PhD, CEO, Cytovation is a clinical stage immune-oncology company focused on the development of CyPep-1, an immunotherapy targeting the cell membrane of tumor cells. CyPep-1 has a multi-modal mechanism of action, eliminating cancer cells by forming pores in the plasma membrane, releasing antigens to the immune system, promoting an inflammatory microenvironment, and inducing a tumor-specific immune response by in situ vaccination.The company is a spin-off from the University of Bergen (Norway).
eXmoor Pharma完成3500万美元A轮融资，投资方为Kineticos、MVM Life Science Partners，是一家英国CGT manufacturing partner。
Led by CEO Angela Osborne, eXmoor pharma is a one-stop cell and gene therapy partner accelerating the manufacturing journey from research to patients. Founded in 2004, the company has specialized in the CGT sector since 2007 helping organizations understand, plan and implement the appropriate CMC strategy. The company does this via its translation and capital consulting groups, process and analytical development labs and now GMP manufacturing capability.
eXmoor has completed over 500 projects for 150 organisations, with 80 current employees, with plans to grow to 200 by 2027. The new Cell and Gene Therapy Centre, opening in Bristol in July 2023, will feature a mixture of manufacturing cleanrooms, Process and Analytical Development and QC laboratories, and associated support spaces suitable for all types of CGTs.
Yuvo Health是一家医疗保健服务商，专注于为FQHC提供护理行政管理承包服务，帮助患者提供医疗初级保健服务。近日获得2020万美元A轮融资，Mastry Ventures领投，AlleyCorp 、New York Ventures、Social Innovation Fund、Vamos Ventures 、HLM Venture Partners、Route 8 Ventures、AV5 Ventures参投。
Launched in January 2021 and led by CEO Cesar Herrera, Yuvo Health partners with healthcare centers, supporting them every step of the way as they extend their reach, while continuing to deliver high quality of care, by leveraging sustainable payment systems, scalable infrastructure, and partnerships within the value-based care ecosystem.The company currently serves community health centers and Independent Physician Associations (IPAs) in the Northeast and Midwest, with plans to expand into other markets soon.
Acurable是一家可穿戴医疗设备研发商，通过其AcuPebble传感器以非侵入性的方式记录呼吸和心脏做功等身体生理过程产生的声学信息，并将其无线传输到移动设备上，信号处理算法将搜集到的声学信号处理后，将自动提取用于诊断和管理重要慢性疾病的主要参数，如睡眠呼吸暂停、癫痫、慢性阻塞性肺病和哮喘等。近日完成1100万欧元的A轮融资。
Led by CEOs Esther Rodriguez-Villegas and Emilio Sanz, Acurable is a medical devices company that creates wearable medical devices intended to be used by patients themselves at home. Its first product AcuPebble SA100 simplifies obstructive sleep apnoea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. AcuPebble SA100 obtained a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home, and received FDA 510(k) clearance in the US.
After launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.
Pomelo Care是一家虚拟医疗服务提供商，旨在解决潜在的风险因素，以改善孕产妇和新生儿的健康，增加获得护理的机会。Pomelo利用数据预测和主动识别风险，利用循证协议和新的护理计划提供整体护理，并通过电话、文本和视频提供全天候护理。近日获得3300万美元种子轮和A轮融资，本轮融资由Andreessen Horowitz领投，First Round Capital、SV Angel、Operator Partners、Allen & Company LLC和BoxGroup跟投。
Led by Marta Bralic Kerns, founder and CEO, Pomelo Care is a virtual medical practice that addresses underlying risk factors to improve maternal and newborn health, increase access to care and reduce avoidable costs. The company supports its patients from preconception through an infant’s first year with personalized and proactive 24/7 care from a dedicated, multispecialty team. Pomelo uses data to predict and proactively identify risk, provides holistic care leveraging evidence-based protocols and novel care programs and makes 24/7 care accessible via phone, text and video.
The company currently serves patients in 44 states and partners with national payers, several of the largest Medicaid managed care organizations in the country, employers including Penn Medicine, Mount Sinai Health System, Koch Industries, Elevance Health, Healthy Blue Nebraska, Nebraska Total Care, a Centene affiliate, and more.（创始人和the Vampire Diary的Cathrine有点神似）
Fuse Oncology完成A轮融资，投资方为Cone Health Ventures、Northeast Georgia Health Ventures、Cone Health Ventures、Northeast Georgia Health Ventures，是一家美国肿瘤医疗保健解决方案提供商。
Led by James Bauler, CEO, Fuse Oncology addresses key challenges that face radiation oncology departments for a more efficient revenue cycle by automatically identifying and tracking missing documentation, incomplete tasks and orders, and wrong charges entered. Its S!GNAL technology catches issues before they materialize to improve revenue cycle and clinical staff workflows. By minimizing mistakes in the coding and documentation process, it has uncovered substantial lost revenues for providers. Additional solutions from Fuse address challenges in the patient engagement cycle to reduce average time to treatment.
The company will use the funds to accelerate expansion of its first commercial product, S!GNAL, and develop additional solutions in the radiation oncology market.The company spun out of Cone Health and signed its first revenues in quarter one of 2022.
PharmEnable是一家英国化学新药研发服务商，专注于化学新体、化学衍生物和复杂化学结构的药物研发，以开发治疗癌症和神经系统疾病的新一代小分子药物为目标。近日完成Pre-A轮融资，总金额为750万美元，由MP Healthcare Venture Management领投，Wren Capital、Martlet Capital、O2h Ventures以及University of Cambridge Seed Funds跟投。
PharmEnable uses its proprietary platform to discover targeted therapies with the aim of replicating the specificity of biologics, but with improved efficacy, absorption and distribution properties enabled by custom-designed oral small molecules, which are also easier to scale and manufacture. The company’s approach combines advanced medicinal chemistry with AI technology, allowing it to unlock challenging biological targets by mapping unexplored chemical space.
PharmEnable has a pipeline of wholly owned oncology programmes, as well as ongoing co-discovery projects with several pharma and biotech companies, including a partnership with Sosei Heptares to unlock novel drug candidates for neurological disease. The wholly owned programmes focus on addressing some of the key challenges in oncology such as tumour penetration and overcoming resistance mechanisms, through designing novel, complex small molecules with improved selectivity and carefully balanced properties.
Alongside the investment, PharmEnable’s Board has been expanded with Dr Jeffrey Moore joining as a Board Director, representing MP Healthcare. Dr Keith Blundy has replaced Dr Christine Martin as an Investor Director on behalf of Cambridge Enterprise.
Nia Health是一家慢性皮肤病数字解决方案提供商，为慢性皮肤病患者提供持续的数字支持。凭借其机器视觉方法，Nia Health能够准确记录疾病和治疗进展优化治疗。近日筹集了350万欧元的种子资金。该轮融资由 High-Tech Gründerfonds 领投。其他投资者包括adesso ventures、Ventura BioMed Investors、Kurt Schwarz博士的基金。
Co-founded by Oliver Welter & Tobias Seidl, Nia Health is a spin-off of the Charité Universitätsmedizin Berlin which develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. With its machine vision approach, Nia Health enables accurate documentation of disease and therapy progression and thus optimised treatment. The company works closely with German patient associations and leading clinicians and has already won reputable customers from the insurance and pharmaceutical industries. Amongst others, the Berlin-based company has developed the apps in the fields of atopic dermatitis (Nia) and psoriasis (Sorea), which were the first digital medical products of their kind to be approved worldwide. The digital medical solutions from Nia Health provide daily support for thousands of patients and their families.
Stepful是一个医疗人员培训平台，利用专有内容提供经济高效的培训，这让更多人能够成为医疗助理，从而打破就业障碍。同时，通过向服务水平低下的社区提供加速培训计划，也能帮助医疗保健雇主拓宽人才招募来源。近日获得750万美元种子轮融资，本轮由Reach Capital领投，YC加速器、EO Ventures和Company Ventures跟投。
Carbogenics是一家生物技术开发商，其下开发了一种称为CreChar的生物添加剂，利用高温低氧过程热解，稳定厌氧消化工厂的性能，并提高食品和农业废物的绿色能源产量。近日获得100万英镑融资，由Green Angel Ventures以及公司现有投资者Scottish Enterprise和Old College Capital。
Founded in 2016 as a spin-out from the University of Edinburgh and led by CEO Ed Craig, Carbogenics develops a bio-additive known as CreChar, which, made utilising a high-temperature low-oxygen process called Pyrolysis, stabilizes the performance of anaerobic digestion plants and enhance green energy production from food and farming waste. This results in higher quantities and quality of biogas and biochar infused digestate which sequesters carbon and enhances the fertilisation process. The product is patent protected in Europe and China.
Based on lab and industrial trials, Carbogenics’ growth plan includes building its first production facility in Perthshire to enable the launch of CreChar into the UK anaerobic digestion market. It’s anticipated the facility will be operational by the end of Q1 2024. The company is also creating new roles across production, operations and business development doubling its size and is in the process of raising further debt and investment finance in the coming months.
BrightHeart完成213.5万美元种子轮融资，投资方为Sofinnova Partners，是一家法国胎儿心脏诊断软件开发商；
Quinky完成10.69万美元种子轮融资，投资方为Antler，是一家荷兰性与关系健康应用程序开发商。
Today Dutch sex-ed startup Quinky announces an early-stage funding round of €100k. The company aims to become "the Duolingo" for sex for Gen-Z folks over 18 years with a gamified sex education app. Quinky is founded by CEO, Mariia Plotkina, a former computer science teacher who started a community called GeekTeachers, and CTO, Neahme Jbaily, a 24-year-old serial entrepreneur originally from Lebanon, where the topic of sex is taboo and highly stigmatised.
Quinky's current funding is from Antler, who also funds sex tech companies Blueheart and Bump'n.The app is in beta tests with plans to roll out the app free to all Gen Zers in Q3. Later there are plans for monetising through subscriptions, an in-app marketplace, and potentially people-matching.
Orthonika，a spin-out from Imperial College London，获得161.6万美元战略投资投资方为Innovate UK，是一家英国膝关节半月板置换研发商。
Orthonika’s total meniscus replacement is an orthopaedic implant for the knee joint that represents an entirely novel solution, replicating the structure and function of the native meniscus in a first-of-its-kind synthetic option for patients. The implant design is unique, featuring an inherent attachment mechanism incorporated into the underlying structure which allows for optimal load transfer and distribution in the knee joint during mobility. Orthonika’s implant aims to restore the biomechanical function of the meniscus to help reduce pain, improve mobility and ultimately delay the onset of osteoarthritis. It is intended to fill the gap between minimally invasive meniscus repair and total knee replacement. This is the fifth Innovate UK grant awarded to Orthonika, bringing total grant funding to £2 million.Dominique Kleyn, Co-Founder and COO。
